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Summary
Constitutive activation of Akt characterizes a high percentage of humanmelanomas and represents a poor prognostic factor
of the disease. We show that Akt transforms melanocytes only in a hypoxic environment, which is found in normal skin. The
synergy between Akt and hypoxia is HIF1amediated. Inhibition of HIF1a decreases Akt transformation capacity in hypoxia
and tumor growth in vivo, while overexpression of HIF1a allows anchorage-independent growth in normoxia and develop-
ment ofmore aggressive tumors. Finally, we show thatmTORactivity is necessary tomaintain the transformed phenotype by
sustaining HIF1a activity. Taken together, these findings demonstrate that Akt hyperactivation and HIF1a induction by nor-
mally occurring hypoxia in the skin significantly contribute to melanoma development.Introduction
Over the past 50 years, the incidence of melanoma has shown
an alarming rate of increase worldwide. Although melanoma ac-
counts for only 10% of all skin cancers, it is responsible for 80%
of all skin cancer deaths (Houghton and Polsky, 2002). Mela-
noma is an aggressive tumor, with a propensity to metastasize,
and is resistant to most current therapeutic regimens (Satya-
moorthy et al., 2001). Environmental stresses together with ge-
netic alterations are key players in melanoma development.
UV exposure, particularly in childhood, represents a key envi-
ronmental risk factor in melanomagenesis (Williams and Ouhtit,
2005). Recent studies have identified the p16INK4A/Rb and
p14ARF/p53 pathways as the main UV targets disrupted in the
early stages of melanoma development (Kannan et al., 2003).
p16INK4A and p14ARF are encoded by the CDKN2a locus at
9p21 via alternative reading frames. CDKN2a is considered
a melanoma susceptibility locus because its loss of function,
commonly seen in the human disease, is necessary although
not sufficient for melanoma development (Sharpless and Chin,
2003). Additional cooperating genetic lesions are required.
Mutations or alterations of the Ras pathway are common
events in melanoma development. Gain-of-function mutationsCANCER CELL : DECEMBER 2005 $VOL. 8 $COPYRIGHT ª 2005 ELSEVIERof NRas and BRaf are found in a large number of primary mela-
nomas and nevi (Davies et al., 2002; Demunter et al., 2001; Papp
et al., 1999; Pollock et al., 2003), while Akt3 has been found hy-
peractivated in 43%–60% of sporadic melanomas as a result of
gene amplification and decreased PTEN protein activity (Stahl
et al., 2004). Interestingly, although activating BRaf mutations
are frequent in melanoma, BRaf appears to be insufficient for
the development of the disease in model systems (Chudnovsky
et al., 2005; Pollock et al., 2003), suggesting that additional
molecular defects may be required. On the other hand, data ob-
tained in transgenic mice (Chin et al., 1997, 1999; Powell et al.,
1999), and more recently in a human melanoma model (Chud-
novsky et al., 2005), have shown that both Ras and phospho-
inositide 3-kinase [PI(3)Kinase] are oncogenes in melanoma,
as active mutants of the two genes are sufficient to induce inva-
sive melanocytic neoplasia. In both cases, concomitant disrup-
tion of the p16INK4A-CDK4-Rb and ARF-HDM2-p53 pathways is
necessary for melanoma development, confirming in experi-
mental models what is commonly observed in the human dis-
ease.
In vivo models allow the study of melanoma development
in a more physiological context where environmental factors
can potentially play a role in the transformation process. InS I G N I F I C A N C E
Melanoma is an aggressive tumor that can metastasize early in the course of the disease and, most importantly, is resistant to most
current therapeutic regimens. Understanding the genetic and environmental factors driving melanomagenesis is essential for the de-
velopment of new therapies. We show that the microenvironment in which melanocytes reside is hypoxic and that this oxygen level is
necessary to allowmelanocyte transformation initiated byAkt; that the synergy between hypoxia andAkt is HIF1a dependent; that the
mTOR pathway is required to maintain the transformed phenotype partially by maintaining HIF1a activity; and that rapamycin effi-
ciently decreasesmelanomadevelopment.We thereforepropose that rapamycin represents a promisinghypoxia-related therapeutic
approach in the treatment of melanoma.INC. DOI 10.1016/j.ccr.2005.11.005 443
A R T I C L Eparticular, the oxygen concentration in tissues is lower than that
in the atmosphere where in vitro experiments are normally per-
formed. Skin, in fact, has been shown to be mildly hypoxic
(Evans and Naylor, 1967; O’Hara et al., 1997; Stewart et al.,
1982), likely due to the distance from the superficial blood ves-
sels. Thus, it seems reasonable to consider such factors when
modeling diseases in vivo and in vitro.
Cells respond to hypoxia by activating the heterodimeric tran-
scription factor hypoxia-inducible factor-1 (HIF-1), composed of
HIF1a and the constitutively expressed HIF1b (ARNT). Under
normoxic or atmospheric O2 levels (21%), hydroxylation of
key proline residues within the regulatory oxygen-dependent
degradation domain (ODD) of the HIF1a subunit facilitates von
Hippel-Lindau protein (pVHL) binding, which in turn allows ubiq-
uitylation and subsequent proteasome-targeted degradation
(Jaakkola et al., 2001; Yu et al., 2001). Under limiting O2 condi-
tions, proline hydroxylation is inhibited, thereby stabilizing HIF1a
subunits, which can then translocate into the nucleus and bind
to constitutively stabilized HIF1b subunits, forming the active
HIF-1 complex.
HIF-1 activates a multitude of O2-responsive genes involved
in various normal cell functions such as survival, apoptosis, glu-
cose metabolism, and angiogenesis. In physiologic hypoxic
conditions, these functions are finely tuned and contribute to
the maintenance of tissue homeostasis. In pathological states,
such as neoplasms, severe hypoxia (<0.5% O2) becomes toxic
for normal and transformed cells unless the latter undergo
genetic and adaptive changes that will allow them to survive.
In this condition, hypoxia significantly contributes to tumor
progression (Harris, 2002). On the other hand, mild hypoxia
(1%–5% O2) has been shown to promote cell proliferation and
survival of different cell types (Alaluf et al., 2000; Balin and Pratt,
2002; Studer et al., 2000); to increase the life span of fibroblasts
and vascular smooth muscle cells (Minamino et al., 2001; Parri-
nello et al., 2003); and to counteract replicative senescence
(Chen et al., 1995; Lee et al., 1999), mainly by decreasing oxi-
dative DNA damage and by activating telomerase via a
HIF1a-dependent mechanism (Nishi et al., 2004; Yatabe et al.,
2004).
Given the various growth-promoting effects of mild hypoxia
through the action of HIF-1, mild hypoxia may be a previously
unappreciated tumor-promoting environmental factor present
in both in vivo models and human disease. In melanoma, this
may be particularly relevant, as nuclear HIF1a staining has
been shown in normal skin (Distler et al., 2004), suggesting
that hypoxic levels of the skin are compatible with HIF1a activity.
Melanocytes reside in such hypoxic milieu, which together with
environmental stresses and genetic alterations, may represent
a promoting factor for melanocyte transformation.
In this work, we show that constitutively active (c.a.) Akt is
able to transformmelanocytes in a hypoxic environment that re-
capitulates in vitro the hypoxic status of the skin. HIF1a is shown
to be required for Akt-dependent transformation of melanocytes
and to be able to enhance Akt oncogenic potential. Moreover,
we show that treatment with rapamycin, a mammalian target
of rapamycin (mTOR)-specific inhibitor, significantly reduces tu-
mor growth and is associated with inhibition of HIF1a activity.
Together, these findings highlight the role of Akt and hypoxia
in melanocyte transformation and support further investigation
of new prevention and therapeutic strategies for melanoma
aimed at the inhibition of HIF1a and Akt pathways.444Results
Human and mouse melanocytes reside
in a hypoxic environment
Both human and mouse skin have been shown to be mildly hyp-
oxic, with oxygen levels ranging between 1.5% and 5% (Evans
and Naylor, 1967; O’Hara et al., 1997; Stewart et al., 1982). As
shown in Figure 1, normal human and mouse skin present hyp-
oxic regions as indicated by positive staining of the hypoxia
markers carbonic anhydrase IX (CAIX) (Figure 1B) (Potter and
Harris, 2003) and 2-nitroimidazole EF5 (EF5) (Figure 1G) (Koch,
2002), respectively. Thesemarkers correlate with glucose trans-
porter-1 (Glut-1) staining, a well-known HIF1a direct target gene
(Figures 1C and 1H), which further supports the idea that the
microenvironment where melanocytes reside is hypoxic and
suitable for HIF1a activity. Indeed, HIF1a localizes in nuclei in
human skin (Figure 1E) and correlates with Glut-1 staining
(Figure 1F). Melanocytes are localized in the dermal epidermal
junction in humans (upper left panels in Figure 1C) and in hair fol-
licles in mice (Figures 1K–1N). These observations support the
notion that the normal microenvironment of the skin is hypoxic,
and this could, potentially, influence melanocyte viability and
proliferation.
Stringent hypoxia is generally associated with cell death,
whereas mild hypoxia has been shown to increase cell life
span and to promote cell immortalization (Parrinello et al.,
2003), a phenomenon that normally preludes transformation.
Cells of the epidermal basal layer stain for the proliferation
marker Ki67 (Figure 1I), indicating that the environment, al-
though hypoxic, is suitable for cell viability. Normal human and
mouse skin did not stain positive for phospho-Akt (Figures 1D
and 1J, respectively).
These findings demonstrate that hypoxia and HIF1a are a fea-
ture of normal skin and may influence the fate of cells acquiring
oncogenic alterations.
Hypoxia cooperates with Akt in promoting
melanocyte transformation
Although hypoxia is typically thought of as a common character-
istic of solid tumors (Harris, 2002), it also appears to be a charac-
teristic of normal skin. To investigate the contributory role of hyp-
oxia to transformation of melanocytes, we infected Ink4a/ARF
knockout cells with c.a. Akt or Ras (V12Ras) and then plated
them in soft agar in normoxic or hypoxic conditions. As previ-
ously shown (Laughner et al., 2001), Akt increased HIF1a levels
under normoxia. Target genes such as Glut-1 and a hypoxia
response element (HRE)-driven reporter construct were also in-
creased. Under hypoxic conditions, HIF1a is further elevated in
both control (pBabe) and Akt cells (Figures 2C and 2D). Similar
results are seen in Ras cells as well (Figure S4D in the Supple-
mental Data available with this article online). Cells expressing
c.a. Akt showed no or poor growth in normoxia despite a high
level of GSK3 phosphorylation, while V12Ras-expressing mela-
nocytes formed numerous colonies in soft agar (Figure 2A and
Figure S4A). On the contrary, the capacity of c.a. Akt-expressing
melanocytes to grow in the absence of substrate was restored in
a low-oxygen environment (2% O2). These results suggest that
hypoxia is required for efficient melanocyte transformation
driven by Akt (Figure 2A, lower panel) andmay aid in transforma-
tion by Ras. Indeed, a slight increase in colony number was alsoCANCER CELL : DECEMBER 2005
A R T I C L EFigure 1. Normal human and mouse skin are hypoxic with low levels of Akt activity
A: Archival normal human skin specimens stained with H&E. B: Normal human skin shows positive staining for the hypoxia marker CAIX. C: The HIF1a-specific
target gene Glut-1 in normal human skin is expressed along the epidermal/dermal junction where melanocytes reside. Upper left panels: melanocytes are
localized in the epidermal/dermal junction and are positive for the melanocyte-specific marker Tyrp-2 (red stain of cytoplasm). D: Absence of activated
Akt in normal human skin as shown by lack of staining with a specific anti-phospho-Akt antibody. E:Normal human skin positively stains for HIF1a. F:Glut-1 stain-
ing of the same human specimen used in E.G:Normal skin fromC3H/HeJmice injectedwith the hypoxic-specificmarker EF5. Hypoxic areas in hair follicles and
epidermis appear in bright red. H: Normal mouse skin shows intense staining for the HIF1a-dependent target Glut-1 in a pattern similar to the hypoxia marker.
I: Ki67 staining of normalmouse skin along the basal layer. J:Akt activity is lowor absent in normalmouse skin as shownby stainingwith a specific anti-phospho-
Akt antibody. Insets fromG to J show staining in hair follicles. K and L:Melanocytes in the hair matrix of the hair follicle of adult C3H/HeJ mice stain positive for
the specific melanocytemarker Tyrp-1 (arrows showmelanocytes).M and N:Melanocytes positive for Tyrp-1 in 5-day-old TP-Ras/C3H/HeJ mice (Powell et al.,
1999). Photographs were taken of serial 5 mm sections of paraffin-embedded normal human skin or frozen mouse skin. Scale bars in A–D, G–K, andM, 50 mm;
scale bars in E, F, and N, 20 mm. L shows a detail from K.observed for V12Ras-expressing melanocytes grown in hypoxia
(Figure S4). Thus, mild hypoxia appears to be a more suitable
environment for efficient transformation in general.
Active Akt has been shown to increase glucose consumption
(Elstrom et al., 2004). We examined whether glucose depletion
from the culture media might inhibit colony formation in soft
agar. We found glucose consumption to be minimal overall
with a slight increase in cells cultured in hypoxia (Figure S1).
These results suggest that a glucose limitation does not affect
colony growth of Akt-expressing melanocytes.
When injected in immunodeficient mice, Akt-expressing me-
lanocytes formed tumors, although they grew at a slower rate
with respect to Ras-expressing cells (Figure 2B). This was sim-
ilar to what we observed in vitro. Since hypoxia is normally
occurring in the skin, it is likely that this hypoxic environment
is contributing to cell growth and tumor formation in vivo.CANCER CELL : DECEMBER 2005HIF1a is necessary for Akt-dependent melanocyte
transformation, and its overexpression allows
anchorage-independent growth under normoxia
HIF1a is a major mediator of the cellular hypoxic response.
The levels of HIF1a increase in cells in vitro after exposure to
an oxygen concentration of <6%–8% (Jiang et al., 1996).
HIF1a becomes rapidly stabilized in response to hypoxia and re-
turns to basal levels after 12–24 hr (Uchida et al., 2004). In our
system, melanocytes exposed to hypoxia exhibit sustained
HIF1a stabilization and activity for up to 20 days (Figure S2), in-
dicating that for the duration of the agar assay (about 3 weeks)
cells continue to express HIF1a and its target genes. Wewanted
therefore to determine whether constant HIF1a activity was
required for Akt to transform melanocytes. To test this, HIF1a
levels were decreased by the use of a specific short interfering
RNA (siRNA). Cells stably expressing this siRNA showed a445
A R T I C L EFigure 2. Akt and hypoxia synergize in transforming melanocytes
A: pBabe-, c.a. Akt-, and V12Ras-expressing cells were seeded in soft agar and incubated in either normoxia (20% O2) or hypoxia (2% O2).
B: Cells described in A were injected s.c. in SCID mice at a density of 106 cells. Tumor volumes were measured and are represented as average 6 SE.
C:Activity of the c.a. Akt was assessed by phosphorylation of its downstream target, GSK3. HIF1aprotein accumulates in hypoxia. HIF1aactivity wasmeasured
by the induction of Glut-1 transcription.
D: HIF1a activity was assessed by the induction of 5XHRE-driven luciferase expression. Luciferase units were normalized for transfection efficiency with
b-galactosidase expression. Results are the mean values 6 SD of triplicates. Results are representative of at least three independent experiments.decreased capacity to upregulate HIF1a under hypoxia (Fig-
ure 3C) and decreased HIF1a activity as demonstrated by re-
duced Glut-1 expression and decreased activity of an HRE-
driven reporter construct (Figures 3C and 3D). Reduced HIF1a
activity resulted in a reduced capacity to grow in soft agar (Fig-
ure 3A) and a significant reduction of tumor growth in vivo. In
fact, tumors formed by cells expressing the siRNA were half
the size of control tumors expressing a scrambled sequence
(Figure 3B).
To further assess the role of HIF1a in melanocyte transforma-
tion, a constitutive form of the molecule was stably transduced
into melanocytes expressing either a control vector (pBabe) or
Akt. This HIF1a species lacks the ODD and therefore is stable
in normoxic conditions. While the endogenous HIF1a is virtually
undetectable (data not shown), HIF1a-ODD (60–70 kDa) is highly
expressed and active in atmospheric oxygen (Figures 4C and
4D). Concomitant presence of active Akt and stable HIF1a pro-
motes melanocyte transformation in vitro in normoxia and con-
fers an increased tumor growth rate of the cells in SCID mice
(Figures 4A and 4B).
These data suggest that HIF1a is a major mediator of the hyp-
oxic effect on Akt-driven melanocyte transformation. Interest-
ingly, expression of c.a. HIF1a alone was not able to transform446melanocytes. This observation suggests that HIF1a may act
mainly as a promoting factor rather than an oncogene per se.
Inhibition of mTOR by rapamycin results
in decreased anchorage-independent growth
of Akt- and Akt/HIF1a-ODD-expressing cells
Akt activates a plethora of signaling cascades involved in a num-
ber of functions, many of which can play a role in tumorigenesis
(Testa and Bellacosa, 2001). mTOR is a downstream effector of
the PI(3)Kinase/Akt pathway, and its functions have been found
to be altered in a variety of tumors bearing alterations of PTEN,
Akt, or other molecules along the pathway. Tumors with altera-
tions in the PI(3)Kinase/Akt/mTOR pathway generally respond
well to treatment with rapamycin, a specific mTOR inhibitor.
This suggests that mTOR has an essential role in maintaining
the transformed phenotype. Although the role of mTOR in mela-
nomas has not been fully addressed, it is conceivable that Akt-
driven melanomas may respond well to rapamycin treatment.
In order to investigate the responsiveness of Akt-expressing
melanocytes to rapamycin, cells were treated with increasing
doses of the drug, and anchorage-independent growth capacity
was analyzed (Figure 5A). The number of colonies in soft
agar decreased significantly at increasing drug concentrationsCANCER CELL : DECEMBER 2005
A R T I C L EFigure 3. HIF1a is required for Akt-dependent melanocyte transformation
A: pBabe- and c.a. Akt-expressing cells stably transfected with either a siRNA specific for mouse HIF1a or a scrambled siRNA sequence were seeded in soft
agar and incubated in 2% O2 for 3 weeks. Colonies were stained with GIEMSA for detection.
B: Cells described in A were injected s.c in SCID mice at a density of 106 cells. Tumor volumes are represented as average 6 SE.
C: Cells using an anti-HIF1a-specific antibody on Akt cells expressing either a siRNA specific for HIF1a (+) or the scrambled sequence (2). HIF1a activity was
determined by induction of Glut-1 transcription. 18S ribosomal RNA was used as a loading control.
D: HIF1a activity was assessed using a 5XHRE-luciferase reporter construct. Results are the mean values 6 SD of triplicates. Results are representative of three
independent experiments.(p < 0.001) for both Akt- and Akt/HIF1a-ODD-expressing mela-
nocytes, indicating that both cell types depend on mTOR func-
tion. On the other hand, rapamycin shows reduced efficacy in
inhibiting colony growth in soft agar of Ras-expressing melano-
cytes (Figure S4A).
Phosphorylation of 4E-BP1, a downstream target of mTOR, is
comparable in cells under normoxia or hypoxia, and rapamycin
inhibits phosphorylation in a dose-dependent manner (Fig-
ure 5B). Similar results were seen for Akt/HIF1a-ODD-expressing
cells under normoxia (Figure 5C) and for Ras-expressing mela-
nocytes (Figure S4C). Phosphorylation of GSK3, a downstream
target of Akt that is independent of mTOR, and phosphorylation
of extracellular signal-regulated kinases (Erk) do not appear to
be inhibited, indicating that rapamycin is specific for its target
molecule.
It has been reported that hypoxia inhibits protein synthesis by
both inactivation (via phosphorylation) of the eukaryotic initiation
factor eIF2a and inhibition of mTOR (Wouters et al., 2005). In our
system, however, we did not observe this inhibitory effect at 2%
oxygen. In fact, mTOR function is maintained, protein synthesis
is slightly increased (Figure S5A), and eIF2a does not appear to
be phosphorylated (Figure S5B). This may be due to the levels of
oxygen used in our experimental settings or to melanocytesCANCER CELL : DECEMBER 2005specifically. Therefore, inhibition of protein synthesis does not
seem to affect our system.
Inhibition of mTOR by rapamycin results in tumor growth
inhibition associated with decreased HIF1a activity
In vitro, rapamycin significantly inhibits anchorage-independent
growth, a characteristic of transformed cells. We next as-
sessed whether rapamycin would inhibit the growth of Akt and
Akt/HIF1a-ODD melanomas in vivo. Cells (10
6 of each type) were
injected in SCID mice and allowed to grow until tumors reached
about 150 mm3 in volume. Tumors were then topically treated
with different doses of rapamycin until the control tumor
reached a volume of about 1–1.2 cm3. As shown in Figure 6, tu-
mor types originating from both Akt-expressing (Figure 6A) and
Akt/HIF1a-ODD-expressing (Figure 6B) cells respond well to ra-
pamycin, showing a significant (p < 0.05) decrease in growth,
especially at the highest dose used. At 100 mM, both tumor
types are about 70% smaller than control tumors. The effect
of rapamycin appears to be mainly cytostatic. In fact, whereas
no significant difference was observed in TUNEL staining be-
tween ethanol-treated and rapamycin-treated tumors (data not
shown), positivity to the proliferation marker Ki67 was signifi-
cantly reduced in rapamycin-treated melanomas (Figure 7C).447
A R T I C L EFigure 4. Overexpression of stable HIF1a promotes transformation of Akt-expressing melanocytes in normoxia
A: pBabe- and c.a. Akt-expressing melanocytes were stably transfected with HIF1a-ODD, a normoxia-stable form of HIF1a. Cells were seeded in soft agar for
3 weeks in 20% O2 (normoxia).
B: Cells indicated in A were injected s.c. in SCID mice (106 cells/flank), and mean tumor volume 6 SE is represented.
C: Akt activity is indicated by the phosphorylation of GSK3. Expression of HIF1a-ODD was measured by Western blotting. The molecular weight of HIF1a-ODD is
lower than that of endogenous HIF1a. Glut-1 expression was measured to assess HIF1a-ODD activity.
D: HIF1a-ODD activity was evaluated by using a 5XHRE-luciferase reporter construct. Results are the mean values 6 SD of triplicates. All experiments were per-
formed in normoxia to avoid interference with the endogenous HIF1a.Less intense staining with a phospho-specific antibody against
4E-BP1 in rapamycin-treated tumors indicates that the treat-
ment was effective against its specific target.
Inhibition of mTOR results in decreased HIF1a activity both
in vitro and in vivo and a slight decrease in HIF1a protein accu-
mulation in hypoxia (Figure 7A, upper panel). HIF1a activity was
assessed in vitro as the capacity to transcribe Glut-1 and to ac-
tivate an HRE-luciferase construct (Figures 7A and 7B). In vivo,
inhibition of mTOR results in reduced Glut-1 expression as well
(Figure 7C).
In parallel studies, we examined the effect of rapamycin in
Ras-expressing melanomas. These tumors show a slight resis-
tance to rapamycin treatment. Tumor size is reduced by only
30% with respect to the size of control tumors and only when
the highest concentration of drug was used (Figure S4B). This
effect is accompanied in vitro by a slight reduction of HIF1a pro-
tein and activity (Figure S4D). This is possibly due to the regula-
tion of Akt by Ras, since Akt/mTOR have been shown to regulate
HIF1a translation (Laughner et al., 2001).
In conclusion, the data presented here demonstrate that
mTOR activity is essential for the formation of Akt-driven mela-
nomas, potentially through regulation of protein translation and
HIF1a activity.448Discussion
Disregulation of the PI(3)Kinase/Akt pathway is found in a variety
of cancers (Vivanco and Sawyers, 2002). Recently, active
PI(3)kinase, together with inactivation of the p16INK4A-CDK4-Rb
and ARF-HDM2-p53 pathways, has been shown to be able to
transform human melanocytes (Chudnovsky et al., 2005). These
findings are consistent with observations in human melanomas
in which inactivation of the CDKN2A locus is quite frequent and
where high Akt activity has been associated with development
and progression of melanoma and correlated with poor prog-
nosis (Dai et al., 2005; Stahl et al., 2004). Using murine mela-
nocytes lacking the CDKN2A locus, we found that an active
form of Akt can transform such cells in vitro and induce tumor
growth in vivo. Moreover, we demonstrate that in order to effi-
ciently transform melanocytes, Akt requires hypoxia and the
activity of HIF-1.
Most of the experiments evaluating the transformation poten-
tial of oncogenes in vitro have been carried out in atmospheric
oxygen. This condition is not representative of the much lower
oxygen tension found in tissues that constitute the native envi-
ronment in which transformation processes are likely to happen.
It has been reported that human skin is mildly hypoxic, withCANCER CELL : DECEMBER 2005
A R T I C L EFigure 5. Inhibition of mTOR activity by rapamycin reduces melanocyte transformation by Akt and HIF1a in vitro
A: Akt- or Akt/HIF1a-ODD-expressing melanocytes were seeded in soft agar containing increasing concentrations of rapamycin (1 nM, 10 nM, and 100 nM).
Cells were incubated in normoxia (20%O2) and hypoxia (2% O2), as indicated, for 3 weeks. Average numbers of colonies6 SD from four independent experi-
ments are indicated. Differences between rapamycin- and vehicle-treated cells (0 mM rapamycin) are statistically significant (*p < 0.001, Student’s t test).
B: The efficacy of the rapamycin treatment on Akt- and Akt/HIF1a-ODD-expressing melanocytes was evaluated as the inhibition of activation (phosphoryla-
tion) of themTOR target 4E-BP1 in both normoxia andhypoxia. TheAkt downstreameffectorGSK3was usedas acontrol for specificity of the treatment; b-actin
was used as a loading control.oxygen levels ranging from 1.5% to 5%O2 (O’Hara et al., 1997).
Here, we show that normal human skin presents high levels of
CAIX and Glut-1 (Airley et al., 2003) and stains positively for
HIF1a, strongly suggesting that hypoxia is a normal characteris-
tic of the tissue microenvironment. This was further confirmed in
mice injected with EF5. EF5 is a specific metabolic marker of
hypoxia, as it binds to cellular macromolecules only in regions
characterized by low oxygen concentrations (Koch, 2002). In
mouse skin, we observed intense staining of the marker, which
also correlated with high expression of Glut-1. Interestingly,
cells in this hypoxic environment stained positive for the prolifer-
ationmarker Ki67, indicating that the hypoxic levels found in skin
are compatible with cell viability and replication.
Our finding is in contrast with other reports in which hypoxia
was shown to inhibit cell growth by inducing p27 and by hypo-
phosphorylating pRB (Gardner et al., 2001; Green et al., 2001).
However, in these other studies very low oxygen tensions
(0.01%) were used. On the contrary, it has been demonstrated
in other experimental settings that mild hypoxia (2%–3% O2)
can increase cell life span by decreasing oxidative DNA damage
and by increasing telomerase activity (Minamino et al., 2001;
Nishi et al., 2004; Parrinello et al., 2003; Yatabe et al., 2004).
Similar experiments have not been reported for melanocytes.
However, melanocytes reside in the epidermal/dermal junction
in humans and are mainly localized in the hair follicles in mice
(Botchkareva et al., 2003), regions that we show to be normally
mildly hypoxic, with constitutive HIF1a activity. Thus, melano-
cytes appear to benefit from the mild hypoxic environment inCANCER CELL : DECEMBER 2005which they reside as opposed to the stressful conditions of se-
vere hypoxia.
In the genesis of melanoma, melanocytes acquire a series of
modifications that are the result of disruptionof skin homeostasis
and genetic alterations. Although Akt activity is absent in normal
skin, it increasesduringmelanomagenesis.Dysplastic nevi show
a mild positivity for phospho-Akt, which increases with progres-
sion toward an invasive tumor (Dai et al., 2005; Stahl et al., 2004).
PI(3)kinase has been shown to be able to transformhumanmela-
nocytes in an in vivo model of regenerated skin (Chudnovsky
et al., 2005).Weshow that overexpression ofAkt, a critical down-
stream effector of PI(3)kinase, transforms melanocytes, which
become able to form tumors. Interestingly, these cells show little
or no capacity to grow in soft agar unless they are placed in mild
hypoxia. Preliminary data with NIH3T3 fibroblasts expressing
Akt suggest that the transforming capacity of the oncogene in
hypoxia may be cell specific. In fact, hypoxia did not seem to in-
crease transformation of these cells (data not shown). These ob-
servations suggest that thephysiologic environment of the skin is
playing a role in promoting melanocyte transformation and that
hypoxia is promoting tumor growth in vivo.
HIF1a plays a major role in the cellular response to hyp-
oxia (Giaccia et al., 2003). Downregulation of HIF1a in Akt-
expressing cells inhibits their ability to grow in soft agar in hyp-
oxia and significantly reduces tumor growth. On the other hand,
by expressing a stable HIF1a, these cells display a fully trans-
formed phenotype in normoxia, clearly demonstrating that
HIF1a is the mediator of the hypoxia-Akt synergism. This is in449
A R T I C L EFigure 6. Rapamycin treatment inhibits growth
of Akt- and Akt/HIF1a-ODD-expressing melano-
cytes in vivo
A:Cells (106) expressing c.a. Akt were injected in
each flank of three SCID mice for a total of six
tumors per group of treatment. Tumors were
treated topically with rapamycin (1 mM, 10 mM,
or 100 mM)when tumor volumes reached approx-
imately 150 mm3. Treatments were done every
other day for the duration of the experiment.
Average tumor volumes 6 SE are shown.
B: Akt/HIF1a-ODD-expressing melanocytes (10
6)
were injected s.c. in each flank of three SCID
mice for a total of six tumors. Treatment with ra-
pamycin started when tumors were approxi-
mately 150 mm3. Mean tumor volumes 6 SE are
represented. Results are representative of three
independent experiments. Statistically signifi-
cant differences from the vehicle-treated tu-
mors are indicated (*p < 0.05, Student’s t test).apparent disagreement with a previous report in which Akt and
HIF1awere shown to independently enhance tumor growth and
angiogenesis in a murine hepatoma cell line model (Arsham
et al., 2004). It is possible that a synergism between the two
molecules may be critical in the early events of melanocyte450transformation, whereas already established tumor cells may
contain additional alterations that allow them to grow and in-
duce angiogenesis independently of HIF1a.
HIF1a gain-of-function mutations have not been found in
tumors, likely because various factors can contribute to itsFigure 7. Suppression of mTOR inhibits HIF1a activity and reduces cell proliferation of Akt-dependent tumors
A:Melanocytes expressing c.a. Akt were treated overnight with 100 nM rapamycin either in normoxia or in hypoxia. HIF1a accumulation in hypoxia was as-
sessed by hybridization with an anti-HIF1a-specific antibody on total protein lysates. Anti-b-actin-specific antibody was used as loading control. HIF1a activity
in treated and untreated cells was determined by induction of Glut-1 transcript. Ribosomal RNA (18S) was included as a loading control.
B: HIF1a activity was assessed by using a 5XHRE reporter construct, and luciferase units were normalized for transfection efficiency against b-galactosidase
expression. Values are mean 6 SD of triplicates. Rapamycin-treated cells show a significant decrease in activity in hypoxia (*p < 0.05, Student’s t test).
C: Phospho-Akt, phospho-4E-BP1, Glut-1, and Ki67 staining of sections from Akt-expressing tumors treated with ethanol (vehicle) or 100 mM rapamycin. Scale
bars, 50 mm.CANCER CELL : DECEMBER 2005
A R T I C L Estabilization. Inactivation of the von Hippel-Lindau (VHL) tumor
suppressor gene, which is associated with development of spo-
radic hemangioblastomas and clear cell renal carcinomas, sta-
bilizes HIF1a due to lack of degradation (Kaelin, 2002). Ras,
commonly mutated in a variety of human cancers, contributes
to HIF1a stabilization by inhibiting prolyl hydroxylation (Chan
et al., 2002). Akt/mTOR, a pathway activated in various human
tumors, increases HIF1a synthesis, resulting in increased pro-
tein and activity in normoxia (Laughner et al., 2001). Recently,
it has been shown that the melanocyte-specific transcription
factor microphthalmia-associated transcription factor (MITF) in-
creases HIF1a by inducing its transcription and contributing in
this way to melanoma survival (Busca et al., 2005). Finally, hyp-
oxia is certainly the most relevant environmental factor that
allows HIF1a stabilization by inhibiting prolyl hydroxylases.
Therefore hypoxia, through HIF1a, contributes to melanocyte
transformation in the absence of genetic alterations of HIF1a
itself.
Growing evidence supports a role for the mTOR pathway as
a downstream effector of Akt-dependent tumorigenesis. The
mTOR protein regulates cap-dependent translation and ribo-
some biogenesis, controlling general protein biosynthesis (Alto-
mare et al., 2004; Bjornsti and Houghton, 2004; Neshat et al.,
2001; Wendel et al., 2004). It has been shown that HIF1a activity
is, at least in part, regulated by mTOR (Hudson et al., 2002;
Laughner et al., 2001). Although protein synthesis is inhibited
under severe hypoxia, we show that under a mild hypoxic envi-
ronment, protein synthesis is maintained if not slightly in-
creased. This observation correlates well with the fact that cells
in the skin are viable and actively proliferating, and that Akt-
expressing melanocytes actively grow and form colonies in agar
in 2% O2. In view of these observations, mTOR may represent
a critical mediator of Akt-HIF1a-dependent melanocyte trans-
formation. In fact, treatment with rapamycin abolishes the capa-
bility of the cells to grow in agar and significantly reduces tumor
growth in vivo. This inhibitory effect correlates with a significant
decrease in HIF1a activity that suggests, as it has been ob-
served elsewhere (Majumder et al., 2004), that the antitumor ac-
tivity of rapamycin is mediated, at least in part, through the inhi-
bition of cellular responses to hypoxic stress. Rapamycin exerts
a reduced effect on Ras-expressing melanocytes both in vitro
and in vivo. In some models, Ras-dependent tumors have
been shown to depend on mTOR (Shao et al., 2004; Wislez
et al., 2005). However, Ras activates other signaling pathways
that can contribute to its tumorigenicity. The Raf/MEK/Erk path-
way, for example, is not inhibited by rapamycin, and it has been
previously shown by us and others to be required by Ras for the
maintenance of the malignant phenotype (Bedogni et al., 2004;
Sebolt-Leopold et al., 1999). Ras-expressing melanocytes may
therefore be less dependent on mTOR for survival and pro-
liferation as observed in other experimental systems (Xing and
Orsulic, 2005).
The data presented here show that Akt is an oncogene in mel-
anoma and that the hypoxic environment of normal skin acts as
an environmental promoting factor in melanomagenesis. While
our data support a protumorigenic role of HIF1a, recent studies
proposed a tumor suppressor role for the transcription factor
(Acker et al., 2005). Moreover, Moeller et al. (2005) have shown
that the overall impact of HIF1a on tumor radiosensitivity is
dependent on the microenvironment. This apparent contrast
between studies suggests that HIF1a may play different rolesCANCER CELL : DECEMBER 2005in different systems and environmental contexts and underlines
the importance of understanding what functions HIF1a exerts in
a specific model when targeting the molecule as a therapeutic
approach. Here, we show that disruption of the PI(3)Kinase/
Akt/mTOR pathway significantly reduces Akt-dependent mela-
noma development. Moreover, although the mechanism of
HIF1a regulation by the mTOR pathway is not fully resolved,
and both translational and posttranslational mechanisms may
contribute to its induction, we show that, in the presence of an
mTOR inhibitor, decreased tumor formation correlates with in-
hibition of HIF1a activity, supporting the notion that HIF1a is
required for melanomagenesis. Inhibition of HIF1a activity by ra-
pamycin may therefore represent a potential mechanism for its
inhibitory effect on melanoma growth.
In view of these findings, we suggest that both Akt and HIF1a
may serve as promising therapeutic targets for melanoma treat-
ment. Rapamycin and its analogs have demonstrated impres-
sive antitumor activity in vivo against different tumors (Row-
insky, 2004), and rapamycin has been shown to resensitize
lymphomas to conventional chemotherapies (Wendel et al.,
2004). Rapamycin may therefore represent a new promising
treatment of melanoma.
Experimental procedures
Chemicals
Dimethyl sulfoxide (DMSO) and cholera toxin (CT) were purchased from
Sigma. Phorbol 12-myristate 13-acetate (TPA) was from Alexis. The mTOR
inhibitor rapamycin was obtained from LC Laboratories and dissolved in
DMSO at a concentration of 2 mM. For in vitro studies, the final rapamycin
concentrations were 100 nM, 10 nM, and 1 nM. In vivo, rapamycin was
used at 100 mM, 10 mM, and 1 mM. EF5 was kindly provided by Dr. C. Koch
(Koch et al., 1995). A 10 mM solution was prepared in sterile PBS and stored
at 4ºC.
Cell lines
Mouse Ink4a/ARF knockout melanocytes were maintained in RPMI 1640
supplemented with 10% FBS, 1% glutamine, 1% penicillin-streptomycin,
200 pM CT, and 200 nM TPA.
Plasmids
HumanmyrAktD4-129 (a gift fromDr. Richard Roth, Stanford University) was
subcloned into the retroviral vector pWZL-hygro (hygromycin resistance) be-
tween BamHI and SalI restriction sites. Human HIF1a-ODD (deletion of aa 401
to 603) was kindly provided by Dr. H. Franklin Bunn (Harvard Medical School)
and subcloned into pWZL-blast3 (blasticidin-3 resistance) between BamHI
and ClaI. The HRE luciferase reporter construct was previously described
(Shibata et al., 2000).
Oligos for mouse HIF1a-specific siRNAs were designed according to the
manufacturer’s instructions (BD Biosciences) and synthesized by the Stanford
Protein andNucleic AcidBiotechnologyFacility. The annealed sequenceswere
cloned between BamHI and EcoRI restriction sites into RNAi-Ready pSiren-
RetroQ vector (BD Biosciences). Sequences are as follows: siHIF1a, GTCTAG
AGATGCAGCAAGA; scrambled siHIF1a, TCAGAACGATGACTGAGAG.
Luciferase assays
Cells (5 3 104/well, in 24-well plates) were transfected using Lipofectamine
plus reagent (Invitrogen) as per the manufacturer’s instructions. After 24 hr,
plates were placed at 2% O2 for 16 hr or left in normoxia. Cells were lysed
in 100 ml lysis buffer (Promega), and luciferase activity was determined by
mixing 10 ml of cell extracts and 100 ml of luciferase assay reagent (Promega).
Light production was measured for 10 s in a Monolight 2010 Luminometer
(Analytical Luminescence Laboratory). A b-galactosidase reporter construct
driven by a CMV promoter was cotransfected with the HRE reporter at a ratio
of 1:5, respectively, to assess transfection efficiency. b-galactosidase ex-
pression was measured as per the manufacturer’s instructions (Promega).451
A R T I C L ESoft agar assay
Melanocytes overexpressing Akt, Akt/siHIF1a, and Akt/HIF1a-ODD (2.53 10
4
cells/well, 12-well plates) were suspended in RPMI + 10% FBS containing
0.3% agar and spread onto a 0.6% agar layer. For each experiment, two
sets of plates were prepared; one was left in normoxia, and one was placed
in a three gas incubator set at 2% O2 (Forma Scientific). After 3 weeks, col-
onies were stained with GEIMSA (Schwartz and Ashwell, 2001), and results
were recorded by scanning the plates (Scan Jet 7400 C).
Western blot analysis
All cell types (106 cells/dish, 100 mm dishes) were plated in RPMI-1640 plus
10% FBS, allowed to adhere, and then placed for 16 hr in low-serum media
(0.5% FBS). Total protein was extracted with lysis buffer (9 M urea, 75 mM
Tris-HCl [pH 7.5], and 100 mM 2-mercaptoethanol), and 30 mg per sample
was separated on an 8% (for HIF1a, phospho-GSK3 and HIF1a-ODD) or
12% (for phospho-4E-BP1) SDS-PAGE gel and transferred onto nitrocellu-
lose membranes. Membranes were probed with anti-phospho-GSK3a/b
(Ser21/9), anti-phospho-4E-BP1 (Thr37/46) (1:1000; Cell Signaling Technol-
ogies), and anti-HIF1a (1:1000; Bethyl Laboratories) antibodies. Bands were
detected using ECL Western Blotting Detection Reagents (Amersham Bio-
sciences). Loading was checked with anti-b-actin antibody (C-11, Santa
Cruz Biotechnology). For samples collected in hypoxia, cells were incubated
for 16 hr in a humidified hypoxic workstation (Invivo2, Ruskinn Technologies)
set at 2% O2, and lysis was performed in the chamber to avoid reoxygena-
tion.
Northern blot analysis
Total RNA from all cell types was harvested using TRIzol Reagent (Invitrogen)
as per the manufacturer’s instructions. Hypoxic specimens were collected
after 16 hr incubation in a 2% O2 chamber. RNA samples were resolved on
a 1% formaldehyde gel and transferred to Hybond-N+ membrane (Amer-
sham Biosciences). Blots were hybridized with a-32P-labeled mouse Glut-1
cDNA. The 18S band of ribosomal RNA was used as loading control.
In vivo experiments
Three- to five-week-oldmale SCID (B6.CB17)mice supplied by Stanford Uni-
versity Animal Facility were housed in the sameAALAC-approved facility with
12 hr light cycles. Food and water were provided ad libitum. All experimental
protocols were APLAC approved. Cells (1 3 106) were injected subcutane-
ously (s.c.) in the dorsal flank of mice (three for each treatment group) so
that each mouse bore two tumors. Treatment with rapamycin started when
Akt and Akt/HIF1a-ODD-dependent tumors were about 150 mm
3 in size. Ra-
pamycin was dissolved in ethanol at concentrations of 100 mM, 10 mM, 1 mM,
and 200 ml of these solutions were topically applied on alternate days for the
duration of the experiment. Mice were sacrificed at 34 days (Akt-dependent
tumors) or 26 days (Akt/HIF1a-ODD-dependent tumors) postinjection. Two
hours prior to sacrifice, mice were injected with EF5 (10mM, 10ml/kg). Gross
pathology of each tumor was recorded. Tumors were measured, and tumor
volumewas calculated by the following formula: (W23 L)3 0.52 (W, width; L,
length) (Arbiser et al., 1997). Tumors were frozen in OCT, and 5 mm sections
were cut. Untreatedmice were also injected with EF5 and skin frozen in OCT.
All experiments were performed at least three times.
Immunohistochemistry
Formalin-fixed, paraffin-embedded archival human specimens of normal
skin were treated as follows. Sections (5 mm) were deparaffinized and rehy-
drated in xylene/ethanol baths and antigen unmasked in 10 mM sodium cit-
rate (pH 6) at 95ºC–100ºC for 20 min. For HIF1a staining, slides were also
subjected to treatment in proteinase K solution (25 ml 20 mg/ml proteinase
K, 50 mM Tris-Cl [pH 8], 10 mM EDTA [pH 8]) for 10 min, to increase unmask-
ing of nuclear antigens. Slides were then incubated overnight in primary anti-
bodies followed by biotinylated secondary antibody (1:200; Jackson Labora-
tory) and streptavidin/alkaline phosphatase or streptavidin/horseradish
peroxidase (Vector Labs). Hematoxylin was used as a counterstain. Frozen
mouse skin and tumor sections were incubated with primary antibodies fol-
lowed with biotinylated secondary antibody and Streptavidin/horseradish
peroxidase (Vector Labs). Hematoxylin was used as a counterstain. Sections
were stained with the following antibodies: rat anti-mouse Ki67 (1:50; Dako
Corporation), rabbit anti-phospho-Akt (Ser473) IHC specific (1:50; Cell Sig-
naling Technologies), rabbit anti-phospho-4E-BP1 (Thr37/46) (1:150; Cell452Signaling Technologies), rabbit anti-Glut-1 antibody (1:200; Chemicon Inter-
national), mouse anti-CAIX (clone MN75; 1:50), rabbit anti-tyrosinase-related
protein 1 and 2 (Tyrp-1 and Tyrp-2) (1:100; a gift from Dr. Vincent J. Hearing,
National Cancer Institute), mouse anti-HIF1a (1:20; clone ESEE122; Novus
Biologicals). Staining of hypoxic areas was as previously described (Koch
et al., 1995). Briefly, frozen skin sections were fixed 1 hr in 4% paraformalde-
hyde in PBS at 0ºC and then blocked overnight in 10% skim milk/5%mouse
serum at 4ºC. Finally, sections were incubated forw6 hr at 4ºCwith antibody
ELK-51 (50 mg/ml; Cye-3 conjugated), mounted, and visualized under a fluo-
rescent microscope.
Supplemental data
The Supplemental Data include five supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/6/
443/DC1/.
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